Evidence map›Paper›PMID 35840687›Full record

ArticleScientific reports2022

MIL-125-based nanocarrier decorated with Palladium complex for targeted drug delivery.

Mojtaba Bagherzadeh, Moein Safarkhani, Mahsa Kiani, Fatemeh Radmanesh, Hossein Daneshgar, Amir Mohammad Ghadiri, Fahimeh Taghavimandi, Yousef Fatahi, Nahid Safari-Alighiarloo, Sepideh Ahmadi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. NHFoods (Basel, Switzerland) · 2023
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Mojtaba BagherzadehDepartment of Chemistry, Sharif University of Technology, Tehran, Iran. bagherzadeh@sharif.edu.
Moein SafarkhaniDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Mahsa KianiDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Fatemeh RadmaneshUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hossein DaneshgarDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Amir Mohammad GhadiriDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Fahimeh TaghavimandiDepartment of Chemistry, Sharif University of Technology, Tehran, Iran.
Yousef FatahiNanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Nahid Safari-AlighiarlooEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Sepideh AhmadiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Navid RabieeSchool of Engineering, Macquarie University, Sydney, NSW, 2109, Australia.
Sharif University of Technology · IRIran University of Medical Sciences · IRPohang University of Science and Technology · KRShahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this work was to provide a novel approach to designing and synthesizing a nanocomposite with significant biocompatibility, biodegradability, and stability in biological microenvironments. Hence, the porous ultra-low-density materials, metal-organic frameworks (MOFs), have been considered and the MIL-125(Ti) has been chosen due to its distinctive characteristics such as great biocompatibility and good biodegradability immobilized on the surface of the reduced graphene oxide (rGO). Based on the results, the presence of transition metal complexes next to the drug not only can reinforce the stability of the drug on the structure by preparing π-π interaction between ligands and the drug but also can enhance the efficiency of the drug by preventing the spontaneous release. The effect of utilizing transition metal complex beside drug (Doxorubicin (DOX)) on the drug loading, drug release, and antibacterial activity of prepared nanocomposites on the P. aeruginosa and S. aureus as a model bacterium has been investigated and the results revealed that this theory leads to increasing about 200% in antibacterial activity. In addition, uptake, the release of the drug, and relative cell viabilities (in vitro and in vivo) of prepared nanomaterials and biomaterials have been discussed. Based on collected data, the median size of prepared nanocomposites was 156.2 nm, and their biological stability in PBS and DMEM + 10% FBS was screened and revealed that after 2.880 min, the nanocomposite's size reached 242.3 and 516 nm respectively. The MTT results demonstrated that immobilizing PdL beside DOX leads to an increase of more than 15% in the cell viability. It is noticeable that the AST:ALT result of prepared nanocomposite was under 1.5.

Indexed as

NanocompositesPalladiumAnti-Bacterial AgentsDoxorubicinDrug Delivery SystemsPseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsDoxorubicinPalladium

Identifiers

PMID35840687
PMCPMC9287414
OpenAlexW4285593543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.